nanoPET Pharma GmbH

As a technology and service provider to the biopharmaceutical industry nanoPET focuses on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging. Nanotechnology is a key element of our business and allows us to offer you materials with unique properties. In June 2010 we launched the first comprehensive portfolio of pre‐clincal small animal contrast agents. Twenty‐one products for the main imaging modalities MRI, CT, ultrasound and optical imaging are available to the imaging community worldwide. nanoPET offers the experience of its experts to provide services to biopharmaceutical companies and imaging equipment manufacturers (Consulting & Service). First transactions with major companies highlight the potential for nanotechnology in preclinical research.